$THAR
Tharimmune, Inc. Stock $thar

$thar Overview Financials Valuation SEC Filings Company Website

2022 Q4 Form 10-Q Financial Statement

#000149315222031446 Filed on November 14, 2022

Income Statement

Concept	2022 Q4	2022 Q3	2021 Q3
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.083M	$1.296M	$228.0K
YoY Change	659.63%	468.31%	42.49%
% of Gross Profit
Research & Development	$683.2K	$831.8K	$313.1K
YoY Change		165.65%	95.71%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses	$1.766M	$2.127M	$541.1K
YoY Change	1638.79%	293.17%	69.1%
Operating Profit		-$2.127M	-$541.1K
YoY Change		293.17%
Interest Expense	$0.00		-$235.8K
YoY Change	-100.0%		293.03%
% of Operating Profit
Other Income/Expense, Net	$0.00		-$76.50K
YoY Change	-100.0%		155.0%
Pretax Income	-$1.766M	-$2.127M	-$853.4K
YoY Change	-172.01%	149.28%	108.16%
Income Tax
% Of Pretax Income
Net Earnings	-$1.766M	-$2.127M	-$853.4K
YoY Change	-172.01%	149.28%	108.16%
Net Earnings / Revenue
Basic Earnings Per Share		-$0.18	-$0.13
Diluted Earnings Per Share	-$0.15	-$184.5K	-$75.98K
COMMON SHARES
Basic Shares Outstanding	11.53M shares	11.53M shares	6.357M shares
Diluted Shares Outstanding		11.53M shares

Balance Sheet

Concept	2022 Q4	2022 Q3	2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$6.511M	$7.597M	$45.10K
YoY Change	149224.08%	16744.06%
Cash & Equivalents	$6.511M	$7.597M	$45.10K
Short-Term Investments
Other Short-Term Assets	$178.1K	$236.0K	$369.8K
YoY Change	-71.15%	-36.2%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$6.689M	$7.833M	$414.9K
YoY Change	975.9%	1787.88%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$0.00	$0.00	$0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets	$6.689M	$7.833M	$414.9K
Total Long-Term Assets	$0.00	$0.00	$0.00
Total Assets	$6.689M	$7.833M	$414.9K
YoY Change	975.9%	1787.88%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$954.5K	$536.8K	$1.215M
YoY Change	-34.76%	-55.81%
Accrued Expenses	$190.5K	$179.9K	$458.4K
YoY Change	-40.15%	-60.76%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due		$0.00	$1.221M
YoY Change		-100.0%
Total Short-Term Liabilities	$1.145M	$716.7K	$6.626M
YoY Change	-74.75%	-89.18%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$933.4K
YoY Change	-100.0%	-100.0%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00	$0.00	$933.4K
YoY Change	-100.0%	-100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.145M	$716.7K	$6.626M
Total Long-Term Liabilities	$0.00	$0.00	$933.4K
Total Liabilities	$1.145M	$716.7K	$7.559M
YoY Change	-78.42%	-90.52%
SHAREHOLDERS EQUITY
Retained Earnings	-$15.40M	-$13.60M
YoY Change	122.83%
Common Stock	$1.160K	$1.160K
YoY Change	82.39%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$69.97K	$62.15K
YoY Change
Treasury Stock Shares	90.83K shares	75.11K shares
Shareholders Equity	$5.544M	$7.116M	-$7.145M
YoY Change
Total Liabilities & Shareholders Equity	$6.689M	$7.833M	$414.9K
YoY Change	975.9%	1787.88%

Cashflow Statement

Concept	2022 Q4	2022 Q3	2021 Q3
OPERATING ACTIVITIES
Net Income	-$1.766M	-$2.127M	-$853.4K
YoY Change	-172.01%	149.28%	108.16%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities	-$1.064M	-$1.825M	-$316.8K
YoY Change	13767.93%	476.23%	187.98%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-22.46K	-62.15K	332.6K
YoY Change	-32.06%	-118.69%	107.88%
NET CHANGE
Cash From Operating Activities	-1.064M	-1.825M	-316.8K
Cash From Investing Activities
Cash From Financing Activities	-22.46K	-62.15K	332.6K
Net Change In Cash	-1.086M	-1.888M	15.82K
YoY Change	2566.66%	-12031.23%	-68.36%
FREE CASH FLOW
Cash From Operating Activities	-$1.064M	-$1.825M	-$316.8K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q3	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent		usd
CY2022Q3	HILS	Redemption Liability Current RedemptionLiabilityCurrent		usd
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Treasury Stock Value TreasuryStockValue		usd
CY2022Q3	us-gaap	Interest Expense InterestExpense		usd
CY2022Q3	HILS	Change In Fair Value Of Redemption Liability ChangeInFairValueOfRedemptionLiability		usd
	HILS	Change In Fair Value Of Redemption Liability ChangeInFairValueOfRedemptionLiability		usd
CY2022Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense		usd
CY2022Q3	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent		usd
CY2022Q3	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable		usd
CY2022Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q3	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
	us-gaap	Notes Reduction NotesReduction		usd
	HILS	Unpaid Deferred Offering Costs UnpaidDeferredOfferingCosts		usd
	dei	Entity Central Index Key EntityCentralIndexKey	0001861657
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022Q3	us-gaap	Deferred Offering Costs DeferredOfferingCosts		usd
CY2022Q3	us-gaap	Interest Payable Current InterestPayableCurrent		usd
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims		usd
	HILS	Change In Fair Value Of Redemption Liability ChangeInFairValueOfRedemptionLiability		usd
	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties		usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities		usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities		usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised		usd
	us-gaap	Payments For Repurchase Of Equity PaymentsForRepurchaseOfEquity		usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt		usd
	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1		usd
	us-gaap	Notes Issued1 NotesIssued1		usd
	HILS	Deferred Offering Costs Reclassified Against Common Stock And Additional Paidin Capital Upon Initial Public Offering DeferredOfferingCostsReclassifiedAgainstCommonStockAndAdditionalPaidinCapitalUponInitialPublicOffering		usd
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate		pure
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate		pure
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate		pure
CY2021Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P0Y
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-41210
	dei	Entity Registrant Name EntityRegistrantName	HILLSTREAM BIOPHARMA, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	84-2642541
	dei	Entity Address Address Line1 EntityAddressAddressLine1	1200 Route 22 East
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 2000
	dei	Entity Address City Or Town EntityAddressCityOrTown	Bridgewater
	dei	Entity Address State Or Province EntityAddressStateOrProvince	NJ
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	08807
	dei	City Area Code CityAreaCode	(908)
	dei	Local Phone Number LocalPhoneNumber	955-3140
	dei	Security12b Title Security12bTitle	Common stock, $0.0001 par value
	dei	Trading Symbol TradingSymbol	HILS
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Shell Company EntityShellCompany	false
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	7115909	usd
CY2022Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	11529861	shares
CY2022Q3	us-gaap	Cash Cash	7596667	usd
CY2021Q4	us-gaap	Cash Cash	4356	usd
CY2022Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	235951	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	70670	usd
CY2021Q4	us-gaap	Deferred Offering Costs DeferredOfferingCosts	546651	usd
CY2022Q3	us-gaap	Assets Current AssetsCurrent	7832618	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	621677	usd
CY2022Q3	us-gaap	Assets Assets	7832618	usd
CY2021Q4	us-gaap	Assets Assets	621677	usd
CY2022Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	536838	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1463059	usd
CY2021Q4	us-gaap	Interest Payable Current InterestPayableCurrent	179621	usd
CY2021Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	200000	usd
CY2022Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	179871	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	318223	usd
CY2021Q4	HILS	Redemption Liability Current RedemptionLiabilityCurrent	980233	usd
CY2021Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	1392544	usd
CY2022Q3	us-gaap	Liabilities Current LiabilitiesCurrent	716709	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	4533680	usd
CY2021Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	772899	usd
CY2022Q3	us-gaap	Liabilities Liabilities	716709	usd
CY2021Q4	us-gaap	Liabilities Liabilities	5306579	usd
CY2022Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	11604970	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	6357314	shares
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	11529861	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	6357314	shares
CY2022Q3	us-gaap	Common Stock Value CommonStockValue	1160	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	636	usd
CY2022Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	20794890	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	2225712	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-13617994	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-6911250	usd
CY2022Q3	us-gaap	Treasury Stock Shares TreasuryStockShares	75109	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-4684902	usd
CY2022Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	7832618	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	621677	usd
CY2021Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	0	shares
CY2022Q3	us-gaap	Treasury Stock Value TreasuryStockValue	62147	usd
	us-gaap	Net Income Loss NetIncomeLoss	-6706744	usd
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	831844	usd
CY2021Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	313133	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1595219	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1883808	usd
CY2022Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1295642	usd
CY2021Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	227980	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3520281	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1222616	usd
CY2022Q3	us-gaap	Operating Expenses OperatingExpenses	2127486	usd
CY2021Q3	us-gaap	Operating Expenses OperatingExpenses	541113	usd
	us-gaap	Operating Expenses OperatingExpenses	5115500	usd
	us-gaap	Operating Expenses OperatingExpenses	3106424	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-2127486	usd
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-541113	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-5115500	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-3106424	usd
CY2021Q3	us-gaap	Interest Expense InterestExpense	235822	usd
	us-gaap	Interest Expense InterestExpense	1591244	usd
	us-gaap	Interest Expense InterestExpense	572912	usd
CY2021Q3	HILS	Change In Fair Value Of Redemption Liability ChangeInFairValueOfRedemptionLiability	76501	usd
	HILS	Change In Fair Value Of Redemption Liability ChangeInFairValueOfRedemptionLiability	980245	usd
CY2021Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-312323	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1591244	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1553157	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-2127486	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-853436	usd
	us-gaap	Net Income Loss NetIncomeLoss	-6706744	usd
	us-gaap	Net Income Loss NetIncomeLoss	-4659581	usd
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.18
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.13
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.60
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.73
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	11531899	shares
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	6357314	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	11248041	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	6357314	shares
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	-6295581	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-853436	usd
CY2021Q3	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	4435	usd
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	-7144582	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-3717528	usd
	us-gaap	Net Income Loss NetIncomeLoss	-4659581	usd
	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	1232527	usd
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	-7144582	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	9040077	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-2127486	usd
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	240762	usd
CY2022Q3	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	37444	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	7115909	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-4684902	usd
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	24389	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	165281	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-99078	usd
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-558837	usd
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	440231	usd
	HILS	Increase Decrease In Interest Payable IncreaseDecreaseInInterestPayable	7237	usd
	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	598694	usd
	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	100000	usd
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	12945082	usd
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	12945082	usd
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	4901537	usd
	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	62147	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	7115909	usd
	us-gaap	Net Income Loss NetIncomeLoss	-6706744	usd
	us-gaap	Net Income Loss NetIncomeLoss	-4659581	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	1569003	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	455003	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	598694	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1232527	usd
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	100000	usd
	HILS	Change In Fair Value Of Redemption Liability ChangeInFairValueOfRedemptionLiability	980245	usd
	HILS	Increase Decrease In Interest Payable IncreaseDecreaseInInterestPayable	117844	usd
	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	-200000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-138352	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	256084	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5494280	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1078569	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	24389	usd
	us-gaap	Payments For Repurchase Of Equity PaymentsForRepurchaseOfEquity	62147	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	13645643	usd
	us-gaap	Payment Of Financing And Stock Issuance Costs PaymentOfFinancingAndStockIssuanceCosts	521294	usd
	us-gaap	Payment Of Financing And Stock Issuance Costs PaymentOfFinancingAndStockIssuanceCosts	106202	usd
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	1038014	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	13086591	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	931812	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	7592311	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-146757	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	4356	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	191852	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	7596667	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	45095	usd
	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	3734446	usd
	us-gaap	Notes Issued1 NotesIssued1	186858	usd
	us-gaap	Notes Reduction NotesReduction	980233	usd
	HILS	Unpaid Deferred Offering Costs UnpaidDeferredOfferingCosts	259723	usd
	HILS	Deferred Offering Costs Reclassified Against Common Stock And Additional Paidin Capital Upon Initial Public Offering DeferredOfferingCostsReclassifiedAgainstCommonStockAndAdditionalPaidinCapitalUponInitialPublicOffering	37342	usd
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1628813	shares
	us-gaap	Operating Income Loss OperatingIncomeLoss	-5100000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5500000	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-13600000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_845_eus-gaap--UseOfEstimates_zGQwvefQ3zt3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_862_zssv2tGw7uv3">Use of Estimates</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Management bases its estimates on historical experience and on assumptions believed to be reasonable under the circumstances. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes, and management must select an amount that falls within that range of reasonable estimates. Estimates are used in the following areas, among others: research and development expense recognition, valuation of common shares and stock options, allowances of deferred tax assets, valuation of debt related instruments, accrued expenses and liabilities, and cash flow assumptions regarding going concern considerations. Given the situation surrounding the COVID-19 pandemic, many estimates and assumptions have required increased judgment and are subject to a higher degree of variability and volatility. Although management believes the estimates that have been used are reasonable, as events continue to evolve and additional information becomes available, actual results could vary from the estimates that were used.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_846_eus-gaap--ConcentrationRiskCreditRisk_zcDwmEmSb8Cj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86C_zxefKvPqFaI1">Concentration of Credit Risk</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company maintains cash balances with various financial institutions. Account balances at these institutions are insured by the Federal Deposit Insurance Corporation up to $<span id="xdx_908_eus-gaap--FederalDepositInsuranceCorporationPremiumExpense_c20220101__20220930_zFq0CWZdfRz3" title="Federal deposit">250,000</span> per depositor. At various times during the year, bank account balances may have been in excess of federally insured limits. The Company has not experienced losses in such accounts. <span style="background-color: white">The Company believes that it is not subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
	us-gaap	Federal Deposit Insurance Corporation Premium Expense FederalDepositInsuranceCorporationPremiumExpense	250000	usd
CY2022Q3	us-gaap	Prepaid Expense Current And Noncurrent PrepaidExpenseCurrentAndNoncurrent	61000	usd
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.34
CY2021Q4	us-gaap	Prepaid Expense Current And Noncurrent PrepaidExpenseCurrentAndNoncurrent	61000	usd
CY2021Q4	us-gaap	Convertible Debt ConvertibleDebt	2165443	usd
CY2022Q3	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	1-for-26.4
CY2021Q3	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	1-for-26.4
	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	1-for-26.4
	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	1-for-26.4
	us-gaap	Interest Expense Debt InterestExpenseDebt	1600000	usd
CY2021Q3	us-gaap	Interest Expense Debt InterestExpenseDebt	236000	usd
	us-gaap	Interest Expense Debt InterestExpenseDebt	573000	usd
CY2021	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	805000	usd
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y6M
CY2021Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	3734446	usd
CY2021Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	1569003	usd
CY2021Q4	us-gaap	Convertible Debt ConvertibleDebt	2165443	usd
CY2021Q4	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	1392544	usd
CY2021Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	772899	usd
CY2020Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	1325288	usd
CY2020Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	1325288	usd
CY2021	HILS	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Initial Embedded Redemption Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityInitialEmbeddedRedemptionValue	1487596	usd
CY2021	HILS	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Change In Fair Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityChangeInFairValue	-1832651	usd
CY2021Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	980233	usd
CY2021Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	980233	usd
CY2021Q3	HILS	Change In Fair Value Of Redemption ChangeInFairValueOfRedemption	76000	usd
	HILS	Change In Fair Value Of Redemption ChangeInFairValueOfRedemption	980000	usd
CY2019Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2022Q2	us-gaap	Stock Repurchase Program Number Of Shares Authorized To Be Repurchased StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased	1000000.0	shares
CY2022Q3	us-gaap	Treasury Stock Shares Acquired TreasuryStockSharesAcquired	45109	shares
	us-gaap	Treasury Stock Shares Acquired TreasuryStockSharesAcquired	75109	shares
CY2022Q3	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	37000	usd
	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	62000	usd
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	903468	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.27
	HILS	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1	P7Y10M24D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	980075	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	3.38
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	240526	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.10
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	14204	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	5.28
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0086	pure
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	881952	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	4.91
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P7Y10M24D
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	1628813	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	4.34
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P8Y6M
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.040	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.945	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	1.040	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.113	pure
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0339	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0169	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0339	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0042	pure
CY2022Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.78
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.78
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.70
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	5.47
CY2022Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	1.60
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	1.10
CY2021Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	0.53
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	5.46
CY2022Q3	us-gaap	Share Based Compensation ShareBasedCompensation	240762	usd
CY2021Q3	us-gaap	Share Based Compensation ShareBasedCompensation	4435	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	598694	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	1232527	usd
CY2022Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	2100000	usd
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y10M24D
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Terms Of Award ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward	the Company modified the stock option exercise price for stock options granted during 2020, increasing the exercise price of such stock options (after adjusting for the 1-for-26.4 reverse stock split) from $0.18 or $2.60 to $0.31 or $3.82 per share, respectively

Files In Submission

Name	View Source	Status
0001493152-22-031446-index-headers.html	Edgar Link	pending
0001493152-22-031446-index.html	Edgar Link	pending
0001493152-22-031446.txt	Edgar Link	pending
0001493152-22-031446-xbrl.zip	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
hils-20220930.xsd	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
hils-20220930_cal.xml	Edgar Link	unprocessable
hils-20220930_def.xml	Edgar Link	unprocessable
hils-20220930_pre.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
hils-20220930_lab.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$THAR
Tharimmune, Inc. Stock $thar

2022 Q4 Form 10-Q Financial Statement

#000149315222031446 Filed on November 14, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$THAR Tharimmune, Inc. Stock $thar

2022 Q4 Form 10-Q Financial Statement

#000149315222031446 Filed on November 14, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$THAR
Tharimmune, Inc. Stock $thar